Pfizer
Q4 2022 Earnings Call
Jan 31, 2023, 10:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, everyone, and welcome to Pfizer's fourth quarter 2022 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chris Stevo, senior vice president and chief investor relations officer.
Please go ahead, sir.
Chris Stevo -- Senior Vice President, Investor Relations
Thank you, Chelsea. Good morning. Welcome to Pfizer's fourth quarter earnings call. I'm joined today by Dr.
Albert Bourla, our chairman and CEO; Dave Denton, our CFO; Dr. Mikael Dolsten, president of worldwide research, Development, and Medical. Joining for the Q&A session, we also have Angela Hwang, chief commercial officer and president, global biopharmaceuticals business; Aamir Malik, our chief business innovation officer; Dr. William Pao, our chief development officer; and Doug Lankler, our general counsel.
Before we begin the call, I want to remind you of some logistical items. Materials for this call and other earnings-related materials are on the investor relations section of pfizer.com. You see our forward-looking statements disclaimer on Slide 3, and additional information regarding these statements and our non-GAAP financial measures is available in our earnings release, as well as in our SEC Forms 10-K and 10-Q, under risk factors and forward-looking information, factors that may affect future results. Forward-looking statements on the call are subject to substantial risks and uncertainties speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements.
With that, I'll turn the call over to Albert.
Albert Bourla -- Chairman and Chief Executive Officer
Thank you, Chris. Hello, everyone, and thank you for joining us today. During this morning's call, I will touch on some of our highlights from 2022 and share some thoughts regarding Pfizer's exciting new year and long-term growth plans. 2022 was an outstanding year for Pfizer on multiple fronts.
We exceeded 100 billion in revenue for the first time in our 174-year history. We maintain our industry-leading clinical success rates and further improved our cycle times, which were already well among the industry's best. We were named 10 different best employer lists, including those published by Forbes, LinkedIn, Glassdoor, and others. And most important, more than 1.3 billion patients around the world were treated with our medicines and vaccines, a truly humbling achievement.